独立董事候选人声明与承诺 本人李闻，已充分了解并同意由提名人柯泽慧提名为浙江诚意药 业股份有限公司第五届董事会独立董事候选人。本人公开声明，本人 具备独立董事任职资格，保证不存在任何影响本人担任浙江诚意药业 股份有限公司独立董事独立性的关系，具体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法 规、部门规章及其他规范性文件，具有 5 年以上法律、经济、会计、 财务、管理或者其他履行独立董事职责所必需的工作经验。 本人虽尚未取得上海证券交易所认可的独立董事培训证明:但承 诺参加证券交易所近期组织的独立董事培训并取得相关培训证明。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司 规章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定 （如适用）； （三）中国证监会《上市公司独立董事管理办法》、上海证券交 易所自律监管规则以及公司章程有关独立董事任职资格和条件的相 关规定； （五）中共中央组织部《关于进一步规范党政领导干部在企业兼 职（任职）问题的意见》的相关规定（如适用）； （六）中共中央纪委、教育部、监察 ...

证券代码：603811 证券简称：诚意药业 公告编号：2025-020 浙江诚意药业股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2024年年度股东大会 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 5 月 20 日 9 点 00 分 召开地点：浙江省温州市洞头区化工路 118 号浙江诚意药业股份有限公司洞 头制造部研发大楼会议室 股东大会召开日期：2025年5月20日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 20 日 至2025 年 5 月 20 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间 ...

第四届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603811 证券简称：诚意药业 公告编号：2025-010 浙江诚意药业股份有限公司 一、监事会会议召开情况 1、浙江诚意药业股份有限公司（以下简称"公司"）第四届监事会第十次会 议于 2025 年 4 月 28 日在公司洞头制造部会议室（温州市洞头区化工路 118 号） 以现场方式召开。 2、本次会议通知和材料于 2025 年 4 月 18 日以电话及邮件等方式发送全体 监事。 3、本次会议应参加监事 3 人，实际参加监事 3 人。 4、本次会议由监事会主席曾焕群主持。公司董事会秘书柯泽慧、审计部经 理刘义元列席了本次会议。 5、本次会议召开符合《中华人民共和国公司法》和《浙江诚意药业股份有 限公司章程》等有关规定，会议决议合法有效。 二、监事会会议审议情况 1、审议通过《2024 年度监事会工作报告》 表决结果：3 票同意；0 票反对；0 票弃权。 本议案尚需提交股东大会审议。 2、审议通过《关于会计政策变更的议案》 表决结果：3 ...

证券代码：603811 证券简称：诚意药业 公告编号：2025-009 浙江诚意药业股份有限公司 第四届董事会第十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 1、浙江诚意药业股份有限公司（以下简称"公司"）第四届董事会第十三次会议 于 2025 年 4 月 28 日在洞头制造部研发大楼会议室（温州市洞头区化工路 118 号）以 现场方式召开。 2、本次会议通知和材料于 2025 年 4 月 18 日以电话及邮件等方式发送全体董事、 监事和高级管理人员。 3、本次会议应参加董事9人，实际参加董事9人。 4、本次会议由董事长颜贻意主持，公司监事、高级管理人员、证券事务代表、董 秘助理、审计部经理、投资部经理列席了本次会议。 5、本次会议召开符合《中华人民共和国公司法》和《浙江诚意药业股份有限公司 章程》等有关规定，会议决议合法有效。 二、董事会会议审议情况 1、审议通过《2024 年度董事会工作报告》 表决结果：9 票同意；0 票反对；0 票弃权。 本议案尚需提交股东大会审议。 2、审 ...

证券代码：603811 证券简称：诚意药业 公告编号：2025-011 浙江诚意药业股份有限公司 关于 2024 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●每股分配比例：每股派发现金股利 0.25 元（含税）。 ●本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日期 将在权益分派实施公告中明确。公司因股份回购产生的库存股不参与本次利润分 配。 ●在实施权益分派的股权登记日前公司总股本或库存股发生变动的，拟维持 现金派发每股分配比例不变，相应调整分配总额，并将在相关公告中披露。 ●公司不触及《上海证券交易所股票上市规则》（以下简称《股票上市规则》） 第 9.8.1 条第一款第（八）项规定的可能被实施其他风险警示的情形。 一、利润分配方案内容 （一）利润分配方案的具体内容 根据中汇会计师事务所（特殊普通合伙）出具的标准无保留意见审计报告 ——中汇会审[2025] 2946 号，截至 2024 年 12 月 31 日母公司报表期末未分配 利润为 751,305,084.94 ...

关于浙江诚意药业股份有限公司 非经营性资金占用及其他关联资金往来情况的专项审核说明 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road, Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhcpa.cn 目 录 | | 页 次 | | --- | --- | | 一、非经营性资金占用及其他关联资金往来情况的专项 | | | 审核说明 | 1-2 | | 二、非经营性资金占用及其他关联资金往来情况汇总表 | 3-4 | 中国杭州市钱江新城新业路 8号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zh ...

浙江诚意药业股份有限公司 内部控制审计报告 中国杭州市钱江新城新业路 8号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行在 " www.zhcpa.cn 内部控制审计报告 中汇会审[2025]2948号 浙江诚意药业股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我 们审计了浙江诚意药业股份有限公司(以下简称诚意药业公司)2024年12月31日的 财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》《企业内部控制应用指引》《企业内部控制 评价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是诚意药业 公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 185,591,983.95, representing a 21.26% increase compared to CNY 153,058,271.42 in the same period last year[4] - Net profit attributable to shareholders increased by 40.10% to CNY 45,793,170.61 from CNY 32,684,974.03 year-on-year[4] - Basic and diluted earnings per share both rose by 40.00% to CNY 0.14 from CNY 0.10[4] - Operating profit for Q1 2025 was ¥53,738,813.23, up 43.4% from ¥37,509,072.47 in Q1 2024[21] - Net profit for Q1 2025 was ¥46,868,712.96, representing a 43.2% increase from ¥32,730,039.82 in Q1 2024[21] - Earnings per share for Q1 2025 was ¥0.14, compared to ¥0.10 in Q1 2024[22] Cash Flow - The net cash flow from operating activities surged by 589.62% to CNY 55,507,117.33, up from CNY 8,048,893.69 in the previous year[4] - Cash flow from operating activities for Q1 2025 was ¥55,507,117.33, significantly higher than ¥8,048,893.69 in Q1 2024[25] - The company reported a net cash outflow from investing activities of ¥9,687,122.47 in Q1 2025[25] - Total cash inflow from financing activities amounted to $1,000,000.00, while cash outflow totaled $47,227,623.22, resulting in a net cash flow of -$46,227,623.22[27] - The net increase in cash and cash equivalents was -$558,340.99, with a beginning balance of $169,447,913.66, leading to an ending balance of $168,889,572.67[27] - The cash flow from financing activities showed a significant increase in outflows compared to the previous period, which had outflows of $30,708,485.27[27] - The impact of exchange rate changes on cash and cash equivalents was -$150,712.63[27] Assets and Liabilities - Total assets decreased by 2.79% to CNY 1,680,186,414.91 from CNY 1,728,380,749.86 at the end of the previous year[5] - Total liabilities decreased from ¥463,314,446.90 in the previous period to ¥376,106,697.83[18] - Current liabilities decreased to ¥226,284,989.18 from ¥291,503,720.47, a decrease of about 22.4%[17] - Long-term borrowings decreased to ¥118,508,000.00 from ¥139,308,000.00, a reduction of approximately 14.9%[17] Shareholder Information - The total number of shareholders at the end of the reporting period is 16,520[11] - The largest shareholder, Yan Yiyi, holds 77,192,080 shares, representing 23.58% of the total shares[11] - The company has a total of 4,000,000 shares held by Yan Maolin through a credit securities account[12] - There are no significant changes in the participation of major shareholders in margin financing and securities lending activities[12] Research and Development - Research and development expenses decreased by 34.97%, mainly due to reduced outsourcing and personnel costs[8] - Research and development expenses for Q1 2025 were ¥7,660,759.12, down from ¥11,781,100.15 in Q1 2024[21] Other Financial Metrics - The weighted average return on equity increased by 0.87 percentage points to 3.57% compared to 2.70% at the end of the previous year[5] - Shareholders' equity attributable to the parent company increased by 3.01% to CNY 1,298,022,359.19 from CNY 1,260,084,487.42[5] - Accounts receivable increased to ¥39,679,124.70 from ¥32,909,369.27, indicating a growth of approximately 20.5%[16] - Inventory decreased to ¥118,406,392.38 from ¥131,843,548.31, a decline of about 10.2%[16] - The company recognized a government subsidy of CNY 868,215.62, which is expected to have a continuous impact on its profits[6] - Sales expenses increased to ¥43,626,154.81 in Q1 2025 from ¥39,746,999.05 in Q1 2024[21] Accounting Standards - The company did not apply new accounting standards starting from 2025[27]

Financial Performance - The company's operating revenue for 2024 reached RMB 714,369,070.89, representing a 6.36% increase compared to RMB 671,626,943.73 in 2023[24]. - Net profit attributable to shareholders for 2024 was RMB 200,700,773.72, a 23.21% increase from RMB 162,896,651.50 in 2023[24]. - The net cash flow from operating activities for 2024 was RMB 205,715,849.04, reflecting a 5.61% increase from RMB 194,780,877.43 in 2023[24]. - Total assets at the end of 2024 were RMB 1,728,380,749.86, a decrease of 8.68% from RMB 1,892,765,912.73 at the end of 2023[25]. - The net assets attributable to shareholders increased to RMB 1,260,084,487.42, up 5.68% from RMB 1,192,314,263.44 at the end of 2023[25]. - Basic earnings per share increased by 22.00% to CNY 0.61 compared to CNY 0.50 in 2023[26]. - The company reported a decrease of 18.06% in net profit attributable to shareholders after deducting non-recurring gains and losses, amounting to RMB 126,863,340.37 in 2024[24]. - Net profit attributable to shareholders rose by 6.36% due to increased operating revenue and asset disposal gains from Jiangsu Chengyi[27]. - Net profit excluding non-recurring gains decreased by 17.02% to CNY 0.39 per share, attributed to declining investment income and increased losses from subsidiary San Da Yuan[26][27]. Cash Flow and Investments - The company reported a net cash flow from operating activities of CNY 205,685,928.34 for the year, with a notable increase in Q4 to CNY 100,731,581.70[29]. - The net cash flow from investing activities improved significantly to CNY 26,181,722.11, compared to a negative cash flow of CNY -59,600,658.72 in the previous year, primarily from the sale of fixed assets by a subsidiary[54]. - The company experienced a 55.92% increase in taxes and surcharges, totaling CNY 14,329,993.19, due to higher property and value-added taxes[54]. Market and Product Development - The main product, glucosamine hydrochloride capsules, secured over 41% market share in 9 provinces after winning the national procurement bid in August 2020, with the procurement period ending in October 2023[42]. - The company is actively communicating with provincial institutions for contract renewals to maintain market share and has expanded sales through national procurement across 30 provinces[42]. - New product developments include the successful approval of bone calcitriol soft capsules and levocarnitine injection, with ongoing consistency evaluations for lidocaine injection and amikacin sulfate injection[40]. - The company plans to enhance product research and development, focusing on anti-tumor and liver protection drugs to diversify its product line[48]. - The company has established long-term stable partnerships with well-known pharmaceutical companies, facilitating further cooperation in raw material production[48]. - The company is focusing on high-end small varieties of "marine drugs" and "major disease medications" to drive future growth[103]. Research and Development - The company has over 30 products in development, focusing on marine drugs, geriatric medications, and anti-tumor drugs[88]. - The company holds 21 valid authorized invention patents, with 5 products recognized as "Excellent Industrial Products" in Zhejiang Province[88]. - The company has initiated consistency evaluation for 9 oral solid preparations, with one key product approved[89]. - The company plans to increase investment in drug research and development and strengthen cooperation with research institutions[90]. - The company reported a research and development (R&D) investment of 6.59% of operating revenue, which is lower than the industry average of 7.14%[98]. Governance and Compliance - The company has established a governance structure that complies with relevant laws and regulations, ensuring the protection of shareholder rights and interests[123]. - There are no reported instances of the controlling shareholder interfering with the company's decision-making processes, maintaining operational independence[124]. - The company has implemented strict information disclosure practices to enhance transparency and prevent insider trading, thereby protecting shareholder rights[126]. - The company is committed to improving its governance structure and internal control mechanisms to ensure sustainable development[126]. - The company has not faced any regulatory requirements for rectification regarding its governance practices[126]. Environmental Responsibility - The company has not experienced any environmental pollution incidents or exceeded discharge limits during the reporting period[167]. - The company has established a comprehensive emergency response plan for environmental incidents, which was approved by the local environmental bureau in December 2024[185]. - The company has implemented carbon reduction measures, successfully reducing CO2 equivalent emissions by 537 tons[188]. - The company has committed to avoiding any competitive actions that could harm the interests of Kang Le Pharmaceutical, ensuring compliance with all relevant regulations[190]. Employee and Management Structure - The total employee compensation for the company reached 99,356,459, with an average of 1,124.33 per employee[130]. - The company has a strong leadership team with extensive experience in the pharmaceutical industry, including positions in various pharmaceutical companies and associations[131]. - The company has a diverse board of directors with expertise in finance, law, and pharmaceuticals, which supports its strategic decision-making[132]. - The performance evaluation mechanism for senior management includes a salary structure of "annual salary + annual performance bonus," with 30% of the salary reserved and linked to sales and net profit targets[162].

浙江诚意药业股份有限公司 2024 年度审计报告 中国杭州市钱江新城新业路 8号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhcpa.cn 证明该审计报告是否由具有执业许可的会计师事务所出 "注册会 您可使用手机"扫一扫"或进入 c.mof.gov.cn） 报告编码: 浙25RFS = (http:/ 一、审计报告 1-5 二、财务报表 6-17 (一) 合并资产负债表 6-7 (二) 合并利润表 (三) 合并现金流量表 (四) 合并所有者权益变动表 10-11 (五) 母公司资产负债表 12-13 (六) 母公司利润表 14 (七) 母公司现金流量表 15 (八) 母公司所有者权益变动表 16-17 三、财务报表附注 中国杭州市钱江新城新业路 8号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and ...